|
Commitments and Contingencies - Additional Information (Detail) (USD $)
|
1 Months Ended |
12 Months Ended |
|
Oct. 31, 2013
sqft
|
Dec. 31, 2014
|
| Tampa Facility [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Period of lease |
39 months
|
|
| Rent expense |
|
$ 76,000us-gaap_LeaseAndRentalExpense
/ us-gaap_LeaseArrangementTypeAxis
= ogen_TampaFacilityMember
|
| Area of Office Space Leased |
4,168us-gaap_AreaOfRealEstateProperty
/ us-gaap_LeaseArrangementTypeAxis
= ogen_TampaFacilityMember
|
|
| Lease expiration date |
|
Feb. 28, 2017
|
| Tampa Facility [Member] | Minimum [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Monthly lease payments |
6,426ogen_OperatingLeasesMonthlyRentPayment
/ us-gaap_LeaseArrangementTypeAxis
= ogen_TampaFacilityMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
|
|
| Tampa Facility [Member] | Maximum [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Monthly lease payments |
6,818ogen_OperatingLeasesMonthlyRentPayment
/ us-gaap_LeaseArrangementTypeAxis
= ogen_TampaFacilityMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
|
|
| Alachua Facility [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Period of expired lease |
|
3 years
|
| Period of lease |
|
5 years
|
| Expiration period |
|
2014-12
|
| Rent expense |
|
119,000us-gaap_LeaseAndRentalExpense
/ us-gaap_LeaseArrangementTypeAxis
= ogen_AlachuaFacilityMember
|
| Alachua Facility [Member] | Minimum [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Monthly lease payments |
|
9,641ogen_OperatingLeasesMonthlyRentPayment
/ us-gaap_LeaseArrangementTypeAxis
= ogen_AlachuaFacilityMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
|
| Alachua Facility [Member] | Maximum [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Monthly lease payments |
|
10,851ogen_OperatingLeasesMonthlyRentPayment
/ us-gaap_LeaseArrangementTypeAxis
= ogen_AlachuaFacilityMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
|
| UFRF License Agreements [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Company's obligation to pay from percentage of selling price of product |
|
5.00%ogen_RoyaltyPaymentPercentage
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| Company's obligation to pay from all revenue received from sublicenses |
|
22.00%ogen_RoyaltyPaymentPercentageSublicenses
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| One-time commercialization fee monthly amount for calculation |
|
5,000ogen_MonthlyCalculationOfCommercializationFee
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| Post-commercialization minimum royalty payments |
|
50,000ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| One-time additional royalty payment would be due when total cumulative royalties paid to UFRF exceed amount |
|
2,000,000ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| One-time additional payment to UFRF as a percentage of total royalties due to UFRF |
|
10.00%ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| Minimum annual maintenance payment per license agreement |
|
10,000ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| Aggregate minimum annual maintenance payment |
|
20,000ogen_AggregateMinimumAnnualMaintenancePayment
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| Quarterly maintenance payment to UFRF under installment plan |
|
5,000ogen_MinimumQuarterlyMaintenancePayment
/ us-gaap_TypeOfArrangementAxis
= ogen_UniversityOfFloridaResearchFoundationLicensesMember
|
| Termination notice period |
|
90 days
|
| Texas A and M University License [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Company's obligation to pay from percentage of selling price of product |
|
5.00%ogen_RoyaltyPaymentPercentage
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasaAndMuniversityLicenseMember
|
| Post-commercialization minimum royalty payments |
|
100,000ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasaAndMuniversityLicenseMember
|
| Initial payment to Texas A&M |
|
5,000ogen_InitialPaymentForLicensingAgreement
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasaAndMuniversityLicenseMember
|
| Minimum consideration for the continuation of the license agreement |
|
15,000ogen_MinimumConsiderationForContinuationOfLicenseAgreement
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasaAndMuniversityLicenseMember
|
| Annual maintenance payment under licensing agreement with Texas A&M |
|
100,000ogen_AnnualMaintenancePaymentUnderLicensingAgreement
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasaAndMuniversityLicenseMember
|
| Maximum period to cure the breach |
|
60 days
|
| Termination notice period |
|
90 days
|
| Texas A and M University License [Member] | Phase II Clinical Trial [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Date of milestone achievement under licensing agreement with Texas A&M |
|
Jun. 01, 2019
|
| Milestone payment under licensing agreement |
|
100,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_PhaseTwoClinicalTrialMember
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasaAndMuniversityLicenseMember
|
| Texas A and M University License [Member] | Phase III Clinical Trial [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Date of milestone achievement under licensing agreement with Texas A&M |
|
Jun. 01, 2022
|
| Milestone payment under licensing agreement |
|
150,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_PhaseThreeClinicalTrialMember
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasaAndMuniversityLicenseMember
|
| Texas A and M University License [Member] | Phase I Clinical Trial [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Date of milestone achievement under licensing agreement with Texas A&M |
|
Jun. 01, 2015
|
| Milestone payment under licensing agreement |
|
50,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_PhaseOneClinicalTrialMember
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasaAndMuniversityLicenseMember
|
| Texas A and M University License [Member] | Sale Of Licensed Technology [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Date of milestone achievement under licensing agreement with Texas A&M |
|
Jun. 01, 2025
|
| Milestone payment under licensing agreement |
|
400,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_SaleOfLicensedTechnologyMember
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasaAndMuniversityLicenseMember
|
| Texas A and M University License [Member] | Minimum [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Company's obligation to pay from percentage of selling price of product |
|
2.00%ogen_RoyaltyPaymentPercentage
/ us-gaap_RangeAxis
= us-gaap_MinimumMember
/ us-gaap_TypeOfArrangementAxis
= ogen_TexasaAndMuniversityLicenseMember
|
| Lantibiotic Exclusive Channel Collaboration (ECC) [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Company's obligation to pay from percentage of selling price of product |
|
25.00%ogen_RoyaltyPaymentPercentage
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticEccMember
|
| Company's obligation to pay from all revenue received from sublicenses |
|
50.00%ogen_RoyaltyPaymentPercentageSublicenses
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticEccMember
|
| Number of shares issued |
|
4,392,425us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticEccMember
|
| Maximum percentage of primary investment securities to investment of shares issued |
|
10.00%ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticEccMember
|
| Number of milestones achieved |
|
0ogen_NumberOfMilestonesAchieved
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticEccMember
|
| Termination notice period |
|
90 days
|
| Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Investigational New Drug Application [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Percentage of number of shares of common stock equal to Base Shares |
|
1.00%ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock
/ us-gaap_ProductOrServiceAxis
= ogen_InvestigationalNewDrugApplicationMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticEccMember
|
| Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Clinical Study Phase 2 [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Percentage of number of shares of common stock equal to Base Shares |
|
1.50%ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock
/ us-gaap_ProductOrServiceAxis
= ogen_ClinicalStudyPhaseTwoMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticEccMember
|
| Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Clinical Study Phase 3 [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Percentage of number of shares of common stock equal to Base Shares |
|
2.00%ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock
/ us-gaap_ProductOrServiceAxis
= ogen_ClinicalStudyPhaseThreeMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticEccMember
|
| Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | Filing of First Investigational New Drug Application [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Percentage of number of shares of common stock equal to Base Shares |
|
2.50%ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock
/ us-gaap_ProductOrServiceAxis
= ogen_FilingOfFirstInvestigationalNewDrugApplicationMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticEccMember
|
| Lantibiotic Exclusive Channel Collaboration (ECC) [Member] | First Regulatory Approval of Oragenics Product [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Percentage of number of shares of common stock equal to Base Shares |
|
3.00%ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock
/ us-gaap_ProductOrServiceAxis
= ogen_FirstRegulatoryApprovalOfOragenicsProductMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LantibioticEccMember
|
| LBPs ECC [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Company's obligation to pay from percentage of selling price of product |
|
10.00%ogen_RoyaltyPaymentPercentage
/ us-gaap_TypeOfArrangementAxis
= ogen_LbpsEccMember
|
| Maximum period to cure the breach |
|
60 days
|
| Number of milestones achieved |
|
0ogen_NumberOfMilestonesAchieved
/ us-gaap_TypeOfArrangementAxis
= ogen_LbpsEccMember
|
| Termination notice period |
|
90 days
|
| LBPs ECC [Member] | Phase II Clinical Trial [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Milestone payment under licensing agreement |
|
2,000,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_PhaseTwoClinicalTrialMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LbpsEccMember
|
| Milestone measurement period |
|
30 days
|
| LBPs ECC [Member] | Phase III Clinical Trial [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Milestone payment under licensing agreement |
|
5,000,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_PhaseThreeClinicalTrialMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LbpsEccMember
|
| Milestone measurement period |
|
30 days
|
| LBPs ECC [Member] | Sale Of Licensed Technology [Member] |
|
|
| Commitment And Contingencies [Line Items] |
|
|
| Milestone payment under licensing agreement |
|
$ 10,000,000ogen_LicenseAgreementFutureMilestonePayment
/ us-gaap_ProductOrServiceAxis
= ogen_SaleOfLicensedTechnologyMember
/ us-gaap_TypeOfArrangementAxis
= ogen_LbpsEccMember
|
| Milestone measurement period |
|
30 days
|